Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer

Front Immunol. 2023 Oct 16:14:1265865. doi: 10.3389/fimmu.2023.1265865. eCollection 2023.

Abstract

Immunotherapy has changed the treatment strategy of non-small cell lung cancer (NSCLC) in recent years, among which anti-PD-1/PD-L1 antibodies are the most used. However, the majority of patients with NSCLC do not derive benefit from immune checkpoint inhibitors (ICIs). Vascular abnormalities are a hallmark of most solid tumors and facilitate immune evasion. Thus, combining antiangiogenic therapies might increase the effectiveness of anti-PD-1/PD-L1 antibodies. In this paper, the mechanisms of anti-angiogenic agents combined with anti-PD-1/PD-L1 antibodies are illustrated, moreover, relevant clinical studies and predictive immunotherapeutic biomarkers are summarized and analyzed, in order to provide more treatment options for NSCLC patients.

Keywords: anti-angiogeneic therapy; immune checkpoint inhibitors; immunology; lung cancer; research advance.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-H1 Antigen
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy
  • Lung Neoplasms* / pathology

Substances

  • Immune Checkpoint Inhibitors
  • B7-H1 Antigen

Grants and funding

This work was supported by National key R&D program of China (2022YFC2505000); NSFC general program (82272796); NSFC special program (82241229); CAMS Innovation Fund for Medical Sciences (CIFMS 2022-I2M-1-009; CAMS Key Laboratory of Translational Research on Lung Cancer (2018PT31035); Ministry of Education Innovation Team development project (3332018002) and Aiyou foundation (KY201701).